What is EDSA's current stock price?

EDSA (Edesa Biotech, Inc.) is currently trading at $10.46 with a market cap of $93.0M.

What sector is Edesa Biotech, Inc. in?

Edesa Biotech, Inc. (EDSA) operates in the Healthcare sector, specifically in the Biotechnology industry.

InvestLog

EDSA Edesa Biotech, Inc.

Healthcare

$10.46-3.77%ClosedMarket Cap: $93.0M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

8.47

P/S

0.00

EV/EBITDA

-7.92

DCF Value

$2.00

FCF Yield

-8.2%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-82.3%

ROA

-84.3%

ROIC

-108.0%

Financials

View All

Period	Revenue	Net Income	EPS
Q2 null	$0.00	$-4.2M	$—
Q1 null	$0.00	$-2.2M	$—
Q4 null	$0.00	$-2.2M	$—
FY null	$0.00	$-7.2M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

0 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Buy

2025-11-03

Trading Activity

Insider Trades

View All

Nijhawan Pardeepdirector, 10 percent owner, officer: Chief Executive Officer

SellFri May 01

Nijhawan Pardeepdirector, 10 percent owner, officer: Chief Executive Officer

SellFri Apr 10

Brooks Michael Jofficer: President

BuyWed Mar 11

Nijhawan Pardeepdirector, 10 percent owner, officer: Chief Executive Officer

BuyFri Mar 06

Nijhawan Pardeepdirector, 10 percent owner, officer: Chief Executive Officer

BuyThu Mar 05

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.28

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.

Peers